Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.

Fries C, Burack WR.

Leuk Res. 2018 Dec;75:15-22. doi: 10.1016/j.leukres.2018.10.018. Epub 2018 Nov 3. Review.

PMID:
30445235
2.

Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia.

Hudson CA, Burack WR, Bennett JM.

Leuk Res. 2018 Oct;73:12-15. doi: 10.1016/j.leukres.2018.08.015. Epub 2018 Aug 28. Review.

PMID:
30176385
3.

Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia.

Hudson CA, Burack WR, Leary PC, Bennett JM.

Am J Clin Pathol. 2018 Aug 30;150(4):293-302. doi: 10.1093/ajcp/aqy054.

PMID:
29982327
4.

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW.

Lancet Haematol. 2018 Mar;5(3):e102-e108. doi: 10.1016/S2352-3026(18)30001-2. Epub 2018 Jan 26.

5.

Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment.

Burack WR, Spence JM, Spence JP, Spence SA, Rock PJ, Shenoy GN, Shultz LD, Bankert RB, Bernstein SH.

Blood Adv. 2017 Jul 7;1(16):1263-1273. doi: 10.1182/bloodadvances.2017005892. eCollection 2017 Jul 11.

6.

Green Inclusions in Neutrophils and Monocytes Are an Indicator of Acute Liver Injury and High Mortality.

Patel N, Hoffman CM, Goldman BI, Bentley K, Burack WR, Evans AG.

Acta Haematol. 2017;138(2):85-90. doi: 10.1159/000477794. Epub 2017 Aug 17. No abstract available.

PMID:
28813697
7.

Intravenous immunoglobulin treatment of spleen cells from patients with immune thrombocytopenia significantly increases the percentage of myeloid-derived suppressor cells.

Aslam R, Burack WR, Segel GB, McVey M, Spence SA, Semple JW.

Br J Haematol. 2018 Apr;181(2):262-264. doi: 10.1111/bjh.14542. Epub 2017 Feb 6. No abstract available.

PMID:
28165136
8.

Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.

Reyes-Barron C, Burack WR, Rothberg PG, Ding Y.

Crit Rev Oncog. 2017;22(5-6):559-567. doi: 10.1615/CritRevOncog.2017020588. Review.

PMID:
29604931
9.

Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.

Hunter BD, Herr M, Meacham PJ, Barlaskar F, Evans AG, Burack WR, Liesveld JL, Becker MW, Milner LA, Constine LS, Dhakal S, Barr PM, Friedberg JW, Casulo C.

Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):145-151. doi: 10.1016/j.clml.2016.11.001. Epub 2016 Nov 23.

PMID:
27998707
10.

Langerhans Cell Histiocytosis Shows Distinct Cytoplasmic Expression of Major Histocompatibility Class II Antigens.

Redd L, Schmelz M, Burack WR, Cook JR, Day AW, Rimsza L.

J Hematop. 2016 Sep;9(3):107-112. doi: 10.1007/s12308-016-0272-9. Epub 2016 Mar 10.

11.
12.

Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node.

Nedelkovska H, Rosenberg AF, Hilchey SP, Hyrien O, Burack WR, Quataert SA, Baker CM, Azadniv M, Welle SL, Ansell SM, Kim M, Bernstein SH.

PLoS One. 2016 May 26;11(5):e0155347. doi: 10.1371/journal.pone.0155347. eCollection 2016.

13.

Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.

Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF Jr, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW.

Br J Haematol. 2016 Jan;172(2):208-18. doi: 10.1111/bjh.13818. Epub 2015 Oct 22.

14.

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells.

Evans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL.

Br J Haematol. 2015 Oct;171(2):205-209. doi: 10.1111/bjh.13562. Epub 2015 Jun 18.

PMID:
26084925
15.

Ultradeep analysis of tumor heterogeneity in regions of somatic hypermutation.

Spence JM, Spence JP, Abumoussa A, Burack WR.

Genome Med. 2015 Mar 12;7(1):24. doi: 10.1186/s13073-015-0147-1. eCollection 2015.

16.

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.

Zent CS, Burack WR.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):119-24. doi: 10.1182/asheducation-2014.1.119. Epub 2014 Nov 18. Review.

PMID:
25696844
17.

Systematic review of the effectiveness of fine-needle aspiration and/or core needle biopsy for subclassifying lymphoma.

Frederiksen JK, Sharma M, Casulo C, Burack WR.

Arch Pathol Lab Med. 2015 Feb;139(2):245-51. doi: 10.5858/arpa.2013-0674-RA. Review.

PMID:
25611108
18.

Transformed follicular non-Hodgkin lymphoma.

Casulo C, Burack WR, Friedberg JW.

Blood. 2015 Jan 1;125(1):40-7. doi: 10.1182/blood-2014-04-516815. Epub 2014 Dec 11. Review.

PMID:
25499449
19.

Intraclonal diversity in follicular lymphoma analyzed by quantitative ultradeep sequencing of noncoding regions.

Spence JM, Abumoussa A, Spence JP, Burack WR.

J Immunol. 2014 Nov 15;193(10):4888-94. doi: 10.4049/jimmunol.1401699. Epub 2014 Oct 13.

20.

Extracellular crystals in plasma cell myeloma.

Brown JT, Burack WR, Becker MW, Vlad-Vonica R, Nadasdy T, Bennett JM, Mendler JH.

Leuk Res Rep. 2014 Jun 18;3(2):49-50. doi: 10.1016/j.lrr.2014.04.004. eCollection 2014. No abstract available.

21.

R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.

Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI.

Br J Haematol. 2014 Aug;166(3):382-9. doi: 10.1111/bjh.12906. Epub 2014 Apr 18.

22.

A highly curable lymphoma occurs preferentially in the proximal tibia of young patients.

Subik MK, Herr M, Hutchison RE, Kelly J, Tyler W, Merzianu M, Burack WR.

Mod Pathol. 2014 Nov;27(11):1430-1437. doi: 10.1038/modpathol.2014.51. Epub 2014 Apr 18.

23.

Symposium on Myeloid Neoplasms on June 9, 2012 in honor of Dr. John M. Bennett.

Burack WR.

Leuk Res. 2012 Dec;36(12):1440. doi: 10.1016/j.leukres.2012.09.003. Epub 2012 Oct 3. No abstract available.

PMID:
23040532
24.

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review.

Rauh MJ, Rahman F, Good D, Silverman J, Brennan MK, Dimov N, Liesveld J, Ryan DH, Burack WR, Bennett JM.

Leuk Res. 2012 Jan;36(1):81-6. doi: 10.1016/j.leukres.2011.07.033. Epub 2011 Sep 3. Review.

PMID:
21890199
25.

Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiation.

Hilchey SP, Rosenberg AF, Hyrien O, Secor-Socha S, Cochran MR, Brady MT, Wang JC, Sanz I, Burack WR, Quataert SA, Bernstein SH.

Blood. 2011 Sep 29;118(13):3591-602. doi: 10.1182/blood-2011-03-340646. Epub 2011 Aug 5.

26.
27.

A case of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-unrelated but Epstein-Barr virus-positive primary effusion lymphoma-like lymphoma in the setting of human immunodeficiency virus and hepatitis C virus infection.

Cooper AR, Burack WR, Allerton JP.

Leuk Lymphoma. 2010 Dec;51(12):2303-5. doi: 10.3109/10428194.2010.520775. Epub 2010 Oct 7. No abstract available.

PMID:
20929325
28.

Is the association of "cup-like" nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful?

Bennett JM, Pryor J, Laughlin TS, Rothberg PG, Burack WR.

Am J Clin Pathol. 2010 Oct;134(4):648-52. doi: 10.1309/AJCPULO8SLW0RKJL.

PMID:
20855646
29.

PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection.

Burack WR, Laughlin TS, Friedberg JW, Spence JM, Rothberg PG.

Am J Clin Pathol. 2010 Jul;134(1):104-11. doi: 10.1309/AJCPK6SBE0XOODHB.

30.

The incidence, natural history, biology, and treatment of transformed lymphomas.

Bernstein SH, Burack WR.

Hematology Am Soc Hematol Educ Program. 2009:532-41. doi: 10.1182/asheducation-2009.1.532. Review.

PMID:
20008238
31.

Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.

Hilchey SP, Kobie JJ, Cochran MR, Secor-Socha S, Wang JC, Hyrien O, Burack WR, Mosmann TR, Quataert SA, Bernstein SH.

J Immunol. 2009 Nov 15;183(10):6157-66. doi: 10.4049/jimmunol.0900475. Epub 2009 Oct 28.

32.

Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction.

Vomastek T, Iwanicki MP, Burack WR, Tiwari D, Kumar D, Parsons JT, Weber MJ, Nandicoori VK.

Mol Cell Biol. 2008 Nov;28(22):6954-66. doi: 10.1128/MCB.00925-08. Epub 2008 Sep 15.

34.

Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53.

Seo J, Chung YS, Sharma GG, Moon E, Burack WR, Pandita TK, Choi K.

Oncogene. 2005 Dec 8;24(55):8176-86.

PMID:
16261166
35.

Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation.

Markiewicz MA, Carayannopoulos LN, Naidenko OV, Matsui K, Burack WR, Wise EL, Fremont DH, Allen PM, Yokoyama WM, Colonna M, Shaw AS.

J Immunol. 2005 Sep 1;175(5):2825-33.

36.
37.

The immunological synapse balances T cell receptor signaling and degradation.

Lee KH, Dinner AR, Tu C, Campi G, Raychaudhuri S, Varma R, Sims TN, Burack WR, Wu H, Wang J, Kanagawa O, Markiewicz M, Allen PM, Dustin ML, Chakraborty AK, Shaw AS.

Science. 2003 Nov 14;302(5648):1218-22. Epub 2003 Sep 25.

38.

Cutting edge: quantitative imaging of raft accumulation in the immunological synapse.

Burack WR, Lee KH, Holdorf AD, Dustin ML, Shaw AS.

J Immunol. 2002 Sep 15;169(6):2837-41.

39.

Immature CD4(+)CD8(+) thymocytes form a multifocal immunological synapse with sustained tyrosine phosphorylation.

Hailman E, Burack WR, Shaw AS, Dustin ML, Allen PM.

Immunity. 2002 Jun;16(6):839-48.

40.

Scaffolds, adaptors and linkers of TCR signaling: theory and practice.

Burack WR, Cheng AM, Shaw AS.

Curr Opin Immunol. 2002 Jun;14(3):312-6. Review.

PMID:
11973128
41.

Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo.

Nguyen A, Burack WR, Stock JL, Kortum R, Chaika OV, Afkarian M, Muller WJ, Murphy KM, Morrison DK, Lewis RE, McNeish J, Shaw AS.

Mol Cell Biol. 2002 May;22(9):3035-45.

42.

Regulation of Lck activity by CD4 and CD28 in the immunological synapse.

Holdorf AD, Lee KH, Burack WR, Allen PM, Shaw AS.

Nat Immunol. 2002 Mar;3(3):259-64. Epub 2002 Feb 4.

PMID:
11828322
43.

The immunological synapse.

Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML.

Annu Rev Immunol. 2001;19:375-96. Review.

PMID:
11244041
44.

Signal transduction: hanging on a scaffold.

Burack WR, Shaw AS.

Curr Opin Cell Biol. 2000 Apr;12(2):211-6. Review.

PMID:
10712921
45.
46.

Changes in vesicle morphology induced by lateral phase separation modulate phospholipase A2 activity.

Burack WR, Dibble AR, Allietta MM, Biltonen RL.

Biochemistry. 1997 Aug 26;36(34):10551-7.

PMID:
9265636
47.

The activating dual phosphorylation of MAPK by MEK is nonprocessive.

Burack WR, Sturgill TW.

Biochemistry. 1997 May 20;36(20):5929-33.

PMID:
9166761
48.

Modulation of phospholipase A2: identification of an inactive membrane-bound state.

Burack WR, Gadd ME, Biltonen RL.

Biochemistry. 1995 Nov 14;34(45):14819-28.

PMID:
7578091
49.

Lipid bilayer heterogeneities and modulation of phospholipase A2 activity.

Burack WR, Biltonen RL.

Chem Phys Lipids. 1994 Sep 6;73(1-2):209-22. Review.

PMID:
8001182
50.

Role of lateral phase separation in the modulation of phospholipase A2 activity.

Burack WR, Yuan Q, Biltonen RL.

Biochemistry. 1993 Jan 19;32(2):583-9.

PMID:
8422369

Supplemental Content

Loading ...
Support Center